Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill mor

Trial Details

NCT ID
NCT03418038
Phase
PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ascorbic Acid
  • Carboplatin
  • Cisplatin
  • Cytarabine
  • Dexamethasone
  • Etoposide
Locations (sample)
  • Mankato, Minnesota, United States|44.15906,-94.00915
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Eau Claire, Wisconsin, United States|44.81135,-91.49849
  • La Crosse, Wisconsin, United States|43.80136,-91.23958

Key Eligibility Criteria

  • Age \>= 18 years
  • Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that las…
  • NOTE: Arms A/B - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can …
  • NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →